HRP20151327T1 - Farmaceutska kombinacija za lijeäśenje boli - Google Patents

Farmaceutska kombinacija za lijeäśenje boli Download PDF

Info

Publication number
HRP20151327T1
HRP20151327T1 HRP20151327TT HRP20151327T HRP20151327T1 HR P20151327 T1 HRP20151327 T1 HR P20151327T1 HR P20151327T T HRP20151327T T HR P20151327TT HR P20151327 T HRP20151327 T HR P20151327T HR P20151327 T1 HRP20151327 T1 HR P20151327T1
Authority
HR
Croatia
Prior art keywords
pain
addition salt
dimethylamino
phenol
propyl
Prior art date
Application number
HRP20151327TT
Other languages
English (en)
Croatian (hr)
Inventor
Klaus Schiene
Petra Bloms-Funke
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151327(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HRP20151327T1 publication Critical patent/HRP20151327T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20151327TT 2010-06-15 2011-06-14 Farmaceutska kombinacija za lijeäśenje boli HRP20151327T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15
PCT/EP2011/002905 WO2011157391A1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain
EP11730199.4A EP2582366B1 (en) 2010-06-15 2011-06-14 Pharmaceutical combination for the treatment of pain

Publications (1)

Publication Number Publication Date
HRP20151327T1 true HRP20151327T1 (hr) 2016-01-01

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151327TT HRP20151327T1 (hr) 2010-06-15 2011-06-14 Farmaceutska kombinacija za lijeäśenje boli

Country Status (29)

Country Link
US (3) US8846765B2 (enExample)
EP (2) EP2582366B1 (enExample)
JP (3) JP6133772B2 (enExample)
KR (1) KR101831616B1 (enExample)
CN (1) CN103108631B (enExample)
AR (1) AR081931A1 (enExample)
AU (2) AU2011267474B2 (enExample)
BR (1) BR112012031836A2 (enExample)
CA (1) CA2796774C (enExample)
CL (1) CL2012002551A1 (enExample)
CO (1) CO6602157A2 (enExample)
CY (1) CY1117118T1 (enExample)
DK (1) DK2582366T3 (enExample)
EC (2) ECSP12012217A (enExample)
ES (1) ES2560676T3 (enExample)
HK (1) HK1215787A1 (enExample)
HR (1) HRP20151327T1 (enExample)
HU (1) HUE026619T2 (enExample)
IL (1) IL221926A (enExample)
MX (1) MX2012014482A (enExample)
NZ (1) NZ602625A (enExample)
PE (2) PE20130243A1 (enExample)
PL (1) PL2582366T3 (enExample)
PT (1) PT2582366E (enExample)
RS (1) RS54439B1 (enExample)
RU (2) RU2589692C2 (enExample)
SI (1) SI2582366T1 (enExample)
WO (1) WO2011157391A1 (enExample)
ZA (1) ZA201208646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157391A1 (en) 2010-06-15 2011-12-22 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140136982A (ko) * 2012-03-12 2014-12-01 얀센 파마슈티카 엔.브이. 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
KR102335919B1 (ko) * 2013-01-22 2021-12-07 비스타젠 쎄라퓨틱스, 인크. L-4-클로로키뉴레닌의 투여형 및 치료적 용도
SG11201507347QA (en) 2013-03-15 2015-10-29 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
JP2017514871A (ja) * 2014-05-06 2017-06-08 ノースウェスタン ユニバーシティ Ｎｍｄａｒ調節化合物の組合せ
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3773531A4 (en) 2018-04-12 2021-06-23 Anavex Life Sciences Corp. A2-73 CRYSTALLINE POLYMORPHIC COMPOSITIONS AND METHOD OF USING THEREOF
BR112021017457A2 (pt) 2019-03-05 2021-11-16 Janssen Pharmaceuticals Inc Escetamina para o tratamento de depressão

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
CA2336902C (en) * 1998-07-16 2009-04-21 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an nmda antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
US20060240128A1 (en) 2002-09-09 2006-10-26 Schlagheck Thomas G Combined immediate release and extended release analgesic composition
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
ES2358763T3 (es) 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
NZ571442A (en) 2006-04-28 2011-09-30 Gruenenthal Chemie Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol for treating pain
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
KR20090018863A (ko) * 2006-06-08 2009-02-23 쉬바르츠파르마에이지 통증성 의학적 상태를 위한 치료제 조합
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
RU2493830C2 (ru) 2008-01-25 2013-09-27 Грюненталь Гмбх Лекарственная форма
KR101641519B1 (ko) * 2008-09-05 2016-07-21 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2011157391A1 (en) 2010-06-15 2011-12-22 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
ES2566828T3 (es) 2010-09-21 2016-04-15 Purdue Pharma L.P. Análogos de buprenorfina como agonistas y/o antagonistas del receptor opioide
AP3815A (en) 2010-12-22 2016-09-30 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
AU2012224953C1 (en) 2011-03-04 2017-07-13 Grünenthal GmbH Parenteral administration of tapentadol
EP2844236B1 (en) 2012-04-17 2018-12-19 Purdue Pharma LP Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Also Published As

Publication number Publication date
DK2582366T3 (en) 2015-12-07
JP6133772B2 (ja) 2017-05-24
PE20160531A1 (es) 2016-06-05
AU2011267474A1 (en) 2013-01-10
AU2011267474B2 (en) 2016-05-26
RS54439B1 (sr) 2016-06-30
HK1215787A1 (en) 2016-09-15
KR20130111945A (ko) 2013-10-11
MX2012014482A (es) 2013-02-21
EP2992877A1 (en) 2016-03-09
RU2675261C2 (ru) 2018-12-18
EP2582366B1 (en) 2015-10-28
EP2582366A1 (en) 2013-04-24
PT2582366E (pt) 2016-01-26
ECSP12012217A (es) 2012-11-30
ECSP19047259A (es) 2019-07-31
JP6197007B2 (ja) 2017-09-13
CY1117118T1 (el) 2017-04-05
AU2016219643B2 (en) 2018-04-12
US20170333369A1 (en) 2017-11-23
US10813890B2 (en) 2020-10-27
BR112012031836A2 (pt) 2016-11-08
US20140309311A1 (en) 2014-10-16
ZA201208646B (en) 2013-09-25
RU2589692C2 (ru) 2016-07-10
HUE026619T2 (en) 2016-06-28
CA2796774C (en) 2020-06-02
US20110306674A1 (en) 2011-12-15
WO2011157391A1 (en) 2011-12-22
PE20130243A1 (es) 2013-03-22
CL2012002551A1 (es) 2012-11-09
HK1184370A1 (zh) 2014-01-24
PL2582366T3 (pl) 2016-04-29
JP6423036B2 (ja) 2018-11-14
ES2560676T3 (es) 2016-02-22
CO6602157A2 (es) 2013-01-18
CA2796774A1 (en) 2011-12-22
JP2017141277A (ja) 2017-08-17
CN103108631A (zh) 2013-05-15
AU2016219643A1 (en) 2016-09-15
KR101831616B1 (ko) 2018-04-04
JP2015232015A (ja) 2015-12-24
CN103108631B (zh) 2015-08-26
SI2582366T1 (sl) 2016-02-29
AR081931A1 (es) 2012-10-31
JP2013528629A (ja) 2013-07-11
IL221926A (en) 2015-08-31
RU2013101515A (ru) 2014-07-20
NZ602625A (en) 2014-03-28
US8846765B2 (en) 2014-09-30
RU2016119041A (ru) 2017-11-20

Similar Documents

Publication Publication Date Title
HRP20151327T1 (hr) Farmaceutska kombinacija za lijeäśenje boli
HRP20190500T1 (hr) Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina
HRP20110076T1 (hr) Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol
HRP20110271T1 (hr) Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek)
JP2017141277A5 (enExample)
JP2013542247A5 (enExample)
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
RU2019109695A (ru) Лекарственная форма для пролонгированного ослабления симптомов
SI2849745T1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro(cyclohexane-1,1'-pyrano-(3,4,b)indol)-4-amine and ibuprofen
HRP20171708T1 (hr) FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID
HRP20201844T1 (hr) Biodostupni poliamini
JP2009520010A5 (enExample)
RU2011112443A (ru) Фармацевтическая комбинация, которая содержит 6-диметиламинометил-1-(3-метокси-фенил)-циклогексан-1,3-диол и парацетамол
JP2018504391A5 (enExample)
SI2849747T1 (en) A pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano , 4, b) indol) -4-amine and NSAID
SI2849740T1 (en) A pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro (cyclohexane-1,1'-pyrano , 4, b) indol) -4-amine and paracetamol or propacetamol
JP2013542262A5 (enExample)
HRP20171930T1 (hr) Analozi diazonamida
HRP20171927T1 (hr) Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu
AR105922A1 (es) 1-((6-metoxinaftalen-2-il)metil)-4-(3,3,3-trifluoropropanoil)octahidro-1h-2,6-metanopirrolo[3,2-b]piridin-3-il-pivalato útil en el tratamiento de dolor